Adynxx, Inc. (ADYX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Adynxx, Inc. (ADYX) trades at $0.00 with AI Score 47/100 (Grade C). Adynxx, Inc. is a clinical-stage biopharmaceutical company focused on developing transcription factor decoy technologies for pain and inflammatory diseases. Market cap: $581, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ADYX: ADYX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ADYX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ADYX: the 1 perspectives are evenly split.
How is this calculated? →Adynxx, Inc. (ADYX) Healthcare & Pipeline Overview
Adynxx, Inc. is a clinical-stage biopharmaceutical company specializing in transcription factor decoy technologies for treating pain and inflammatory diseases. Their AYX platform, including brivoligide in Phase II trials, aims to address unmet needs in postoperative and chronic pain management, positioning them within the competitive biotechnology sector.
What Is the Investment Thesis for ADYX?
Adynxx, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead candidate, brivoligide, is currently in Phase II clinical development for postoperative pain, representing a potential near-term catalyst. Success in Phase II trials could significantly increase the company's valuation. However, the company's limited financial resources, with a market cap of 581 and negative free cash flow, pose a significant risk. The negative beta of -6.13 suggests an inverse correlation with the market, which may or may not be desirable. Further, the biotechnology industry is inherently risky, with a high failure rate for clinical trials. The advancement of AYX2, a pre-clinical candidate for focal chronic pain, offers long-term growth potential, but is subject to significant regulatory and development hurdles.
Based on FMP financials and quantitative analysis
ADYX Key Highlights
- Adynxx, Inc. is a clinical-stage biopharmaceutical company focused on pain and inflammatory diseases.
- The company's lead product candidate, brivoligide, is in Phase II clinical development for postoperative pain reduction.
- Adynxx's technology platform is based on transcription factor decoy molecules.
- The company has a pre-clinical candidate, AYX2, for the treatment of focal chronic pain.
- Adynxx, Inc. has a market capitalization of 581 and negative free cash flow.
Who Are ADYX's Competitors?
ADYX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ADYX's Key Strengths?
- Novel transcription factor decoy technology.
- Lead product candidate in Phase II clinical development.
- Experienced management team.
- Focus on unmet medical needs in pain management.
What Are ADYX's Weaknesses?
- Limited financial resources.
- Dependence on a single lead product candidate.
- High risk of clinical trial failure.
- Small number of employees.
What Could Drive ADYX Stock Higher?
- Data readout from Phase II clinical trials for brivoligide in postoperative pain.
- IND filing and initiation of Phase I trials for AYX2 in focal chronic pain.
- Potential partnerships with pharmaceutical companies for late-stage development and commercialization.
- Securing additional funding through venture capital or public offerings.
What Are the Key Risks for ADYX?
- Financial-distress signal — its Altman Z-Score of -30.38 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-70.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of Phase II clinical trials for brivoligide.
- Regulatory delays or rejection of drug candidates.
- Competition from other pain management therapies.
- Limited financial resources and dependence on external funding.
- High risk inherent in biotechnology drug development.
What Are the Growth Opportunities for ADYX?
- Successful completion of Phase II clinical trials for brivoligide in postoperative pain represents a significant growth opportunity. Positive data could lead to partnerships with larger pharmaceutical companies for Phase III development and commercialization. The market for postoperative pain management is estimated to be substantial, with a growing demand for non-opioid alternatives due to the opioid crisis. Timeline: Anticipated data readout from Phase II trials within the next 12-18 months.
- Advancement of AYX2, the pre-clinical candidate for focal chronic pain, into clinical development offers a long-term growth opportunity. Chronic pain affects a significant portion of the population, and there is a need for more effective and targeted therapies. Successful development of AYX2 could expand Adynxx's product pipeline and address a larger market. Timeline: IND filing and initiation of Phase I trials within the next 2-3 years.
- Expansion of the AYX platform to target other inflammatory diseases represents a potential growth opportunity. Transcription factor decoy technology has broad applicability in modulating gene expression and reducing inflammation in various disease states. Adynxx could leverage its expertise to develop new therapies for conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Timeline: Identification of new targets and initiation of pre-clinical studies within the next 3-5 years.
- Strategic partnerships with academic institutions or other biotechnology companies could accelerate the development and commercialization of Adynxx's technology. Collaborations could provide access to new technologies, expertise, and funding. Partnering with established players in the pharmaceutical industry could facilitate the advancement of Adynxx's product pipeline and increase its market reach. Timeline: Ongoing discussions with potential partners.
- Securing additional funding through venture capital or public offerings is essential for supporting the company's clinical development programs and expanding its research and development capabilities. Access to capital will enable Adynxx to advance its product pipeline, conduct clinical trials, and build a commercial infrastructure. Timeline: Seeking funding within the next 6-12 months.
What Opportunities Does ADYX Have?
- Partnerships with larger pharmaceutical companies.
- Expansion of the AYX platform to other inflammatory diseases.
- Growing market for non-opioid pain therapies.
- Positive clinical trial results.
What Threats Does ADYX Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Failure of clinical trials.
- Inability to secure additional funding.
What Are ADYX's Competitive Advantages?
- Proprietary transcription factor decoy technology platform.
- Patent protection for their drug candidates and technology.
- Clinical data supporting the safety and efficacy of brivoligide.
What Does ADYX Do?
Founded in 2007 and headquartered in San Francisco, California, Adynxx, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for pain and inflammatory diseases. The company's core technology revolves around transcription factor decoy molecules, designed to modulate gene expression and reduce inflammation and pain signaling. Adynxx's lead product candidate, brivoligide, is an AYX platform molecule currently in Phase II clinical development for the reduction of postoperative pain. Brivoligide represents a novel approach to pain management by targeting specific transcription factors involved in the inflammatory cascade. In addition to brivoligide, Adynxx is also advancing AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company's focus on transcription factor decoy technology differentiates it from traditional pharmaceutical approaches, offering the potential for more targeted and effective pain management strategies. Adynxx's mission is to address the significant unmet medical needs in pain management and inflammatory diseases through the development of innovative therapies.
What Products and Services Does ADYX Offer?
- Develop transcription factor decoy technologies.
- Focus on treatments for pain and inflammatory diseases.
- Develop the AYX platform of transcription factor decoys.
- Develop brivoligide for postoperative pain reduction (Phase II).
- Develop AYX2 for focal chronic pain (pre-clinical).
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
How Does ADYX Make Money?
- Develop novel therapies for pain and inflammatory diseases.
- Out-license or partner with larger pharmaceutical companies for late-stage development and commercialization.
- Generate revenue through milestone payments and royalties on partnered products.
What Industry Does ADYX Operate In?
Adynxx, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and a high degree of risk. The market for pain management therapies is substantial, driven by an aging population and increasing prevalence of chronic pain conditions. Adynxx's focus on transcription factor decoy technology differentiates it from companies developing traditional small molecule or biologic drugs. The company faces competition from established pharmaceutical companies and other biotechnology firms developing novel pain therapies. Success in this industry requires strong scientific expertise, effective clinical trial execution, and the ability to secure regulatory approvals and commercial partnerships.
Who Are ADYX's Key Customers?
- Pharmaceutical companies seeking novel pain management therapies.
- Patients suffering from postoperative pain.
- Patients suffering from focal chronic pain.
FY2026 estForward Outlook
Wall Street analysts project Adynxx, Inc. revenue of about $19.8M for fiscal 2026, with EPS near $-18.15.
F-Score 2/9Financial Health
Adynxx, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.38 places it in the distress zone, a signal of elevated financial risk.
ROE -70%Key Financial Metrics
Return on equity for Adynxx, Inc. stands at -70.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -87.0%, showing how much profit it generates from its asset base. A current ratio of 6.76 indicates the company holds enough short-term assets to cover its near-term obligations.
Adynxx, Inc. (ADYX) Valuation Context
Valued at 581, ADYX is classified as a micro-cap stock. Relative to its peer group, ADYX's quantitative score of 47/100 is below the peer average of 76/100.
Company Profile
Adynxx, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Richard Orr. ADYX has traded publicly since 1998.
ADYX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Adynxx's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shown an uptick in discussions about Adynxx's innovative approaches, reflecting growing interest among investors.
- Positive developments in clinical trials have sparked optimism around the company's product pipeline, enhancing its market appeal.
- Increased media coverage highlighting Adynxx's advancements in pain management could attract more attention from institutional investors.
Bear Case
- Concerns about the competitive landscape in the biotech sector may dampen enthusiasm, as many companies vie for limited market share.
- Recent social sentiment analysis indicates a rise in skepticism among traders, with some questioning the viability of Adynxx's long-term strategies.
- The lack of significant partnerships or collaborations recently may raise doubts about the company's ability to scale effectively.
- Potential regulatory hurdles in the biotech industry could pose risks, leading to cautious sentiment among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ADYX Latest News
No recent news available for ADYX.
ADYX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADYX.
Price Targets
Wall Street price target analysis for ADYX.
ADYX MoonshotScore
What does this score mean?
The MoonshotScore rates ADYX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ADYX OTC Market Information
ADYX trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
ADYX Healthcare Stock FAQ
What does Adynxx, Inc. do?
Adynxx, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for pain and inflammatory diseases. The company's core technology revolves around transcription factor decoy molecules, designed to modulate gene expression and reduce inflammation and pain signaling. Their lead product candidate, brivoligide, is in Phase II clinical development for postoperative pain, offering a potential non-opioid alternative. Adynxx aims to address significant unmet medical needs in pain management through targeted therapies.
What do analysts say about ADYX stock?
As of March 16, 2026, there is no available analyst coverage for Adynxx, Inc. (ADYX). Given its market capitalization of 581 and clinical-stage status, the company may not be actively followed by major research firms. Potential investors should conduct their own due diligence and consider the inherent risks associated with investing in small-cap biotechnology companies, particularly those with limited financial resources and ongoing clinical trials. The success of brivoligide's Phase II trials will be a key factor in determining the company's future prospects.
What are the main risks for ADYX?
Adynxx, Inc. faces several key risks inherent to the biotechnology industry. The primary risk is the potential failure of its lead product candidate, brivoligide, in Phase II clinical trials. Clinical trial failures are common in biotechnology and can significantly impact a company's valuation. The company also faces regulatory risks associated with obtaining FDA approval for its drug candidates. Furthermore, Adynxx has limited financial resources and is dependent on external funding to support its clinical development programs. Competition from established pharmaceutical companies and other biotechnology firms also poses a threat.
What are the key factors to evaluate for ADYX?
Adynxx, Inc. (ADYX) holds an AI score of 47/100 (low). Not financial advice.
How frequently does ADYX data refresh on this page?
ADYX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ADYX's recent stock price performance?
Adynxx, Inc. (ADYX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel transcription factor decoy technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADYX overvalued or undervalued right now?
Valuing Adynxx, Inc. (ADYX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ADYX?
Before investing in Adynxx, Inc. (ADYX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.